Results 241 to 250 of about 35,513 (277)
Some of the next articles are maybe not open access.
Expert Opinion on Pharmacotherapy, 2002
Meloxicam (Mobic trade mark, Boehringer Ingelheim) is a relatively new oral non-steroidal anti-inflammatory drug (NSAID) approved for the treatment of osteoarthritis in the US. It has also been evaluated for the treatment of rheumatoid arthritis, ankylosing spondylitis and acute 'rheumatic' pain.
Roy, Fleischmann +2 more
openaire +3 more sources
Meloxicam (Mobic trade mark, Boehringer Ingelheim) is a relatively new oral non-steroidal anti-inflammatory drug (NSAID) approved for the treatment of osteoarthritis in the US. It has also been evaluated for the treatment of rheumatoid arthritis, ankylosing spondylitis and acute 'rheumatic' pain.
Roy, Fleischmann +2 more
openaire +3 more sources
Development of hot-melt extruded drug/polymer matrices for sustained delivery of meloxicam
Journal of Controlled Release, 2022Yun-Chu Chen +2 more
exaly
Improving Solubility and Pharmacokinetics of Meloxicam via Multiple-Component Crystal Formation
Molecular Pharmaceutics, 2012Michael J Zaworotko +1 more
exaly
Improved absorption of meloxicam via salt formation with ethanolamines
European Journal of Pharmaceutics and Biopharmaceutics, 2007Hyo-Kyung Han
exaly